Gentil Govantes M A, Vidal Blandino M, Ruiz Esteban P, Rodelo Haad C, Torrado Masero J, Toro Ramos M, Burgos Rodríguez D, Alonso Gil M, Osuna Ortega A, Franco Esteve A
SICATA (Andalusian Transplant Co-ordination Information System), Seville, Spain.
Transplant Proc. 2013;45(10):3624-6. doi: 10.1016/j.transproceed.2013.10.028.
Lymphoproliferative disease (LPD) after renal transplantation (RT) is an unusual complication but one that impacts greatly on survival. We examined possible predisposing factors and their effect on survival using data from the Andalusian Transplant Co-ordination Information System (SICATA) regional computerized database of patients on renal replacement therapy due to chronic kidney disease (CKD).
The study population comprised all RT undertaken at adult centers in Andalusia from January 1, 1990 to December 31, 2009 (N = 5577). We retrospectively analyzed cases at December 31, 2011 (N = 60). A control group comprised the 2 closest RT in time done at the same center and with equal or greater graft survival at the time of diagnosis of LPD in the associated case (N = 120). The basic variables were obtained from the general register (1990-2009) and widened from the specific register (2000-2009). Case-control comparison of survival was done with Kaplan-Meier from diagnosis to death or organ loss censored for death. Cox univariate and multivariate (LPD plus available covariables of demonstrated effect) analyses were done.
We found no significant differences between cases and controls regarding the characteristics of the recipient or of the donor/organ, initial immunosuppression by intention to treat, or post-RT course. The impact on recipient survival 5 years after diagnosis was as follows: LPD, 35%; controls, 90% (P < .000). Cox univariate analysis showed the relative risk (RR) of death for LPD was 11.36 (95% confidence interval [CI], 6.2-20.9; P < .000) and the multivariate analysis showed relative risk (RR) = 13.87 (7.45-25.3; P < .000). The impact on death-censored graft survival 5 years after diagnosis was as follows: LPD, 65%; controls, 87% (P = .007). Cox univariate analysis was as follows: RR of failure for LPD, 2.70 (95% CI, 1.3-5.7; P = .009).
We found no significant differences between LPD cases and contemporary controls regarding the basic characteristics of the recipient, donor/organ, initial immunosuppression, or initial graft evolution. There was an enormous impact on both patient and graft survival.
肾移植(RT)后淋巴增殖性疾病(LPD)是一种罕见的并发症,但对生存率有很大影响。我们利用安达卢西亚移植协调信息系统(SICATA)区域计算机数据库中因慢性肾脏病(CKD)接受肾脏替代治疗患者的数据,研究了可能的易感因素及其对生存率的影响。
研究人群包括1990年1月1日至2009年12月31日在安达卢西亚成人中心进行的所有肾移植(N = 5577)。我们回顾性分析了2011年12月31日的病例(N = 60)。对照组包括在同一中心进行的时间上最接近的2例肾移植,且在相关病例LPD诊断时具有相同或更高的移植物生存率(N = 120)。基本变量从总登记册(1990 - 2009年)获取,并从特定登记册(2000 - 2009年)进行扩充。采用Kaplan - Meier法对从诊断到死亡或因死亡而截尾的器官丢失的生存率进行病例对照比较。进行Cox单因素和多因素(LPD加上已证明有影响的可用协变量)分析。
在受者、供者/器官的特征、按意向性治疗的初始免疫抑制或肾移植后的病程方面,病例组和对照组之间未发现显著差异。诊断后5年对受者生存率的影响如下:LPD组为35%;对照组为90%(P <.000)。Cox单因素分析显示LPD死亡的相对风险(RR)为11.36(95%置信区间[CI],6.2 - 20.9;P <.